Kent Pharmaceuticals Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kent Pharmaceuticals Limited - overview
Established
1986
Location
Ashford, Kent, UK
Primary Industry
Pharmaceuticals
About
Kent Pharmaceuticals Limited is a UK-based company that specializes in the development, in-licensing, and commercialization of value-added pharmaceuticals, offering over 200 products tailored to healthcare providers. Kent Pharmaceuticals Limited, founded in 1986 and headquartered in Ashford, UK, specializes in the pharmaceutical sector. In June 2019, Duke Street, along with the company's management, acquired Kent Pharmaceuticals from DCC Vital Ltd, completing the transaction in September 2019. The founder's history and previous ventures are not available.
Kent Pharmaceuticals Limited, operating under the Kent-Athlone Pharma Group, focuses on the development, in-licensing, and commercialization of over 200 pharmaceutical products. Their portfolio includes ampoules and over-labelling services designed specifically for UK hospitals and healthcare facilities. The company prioritizes innovative solutions that enhance medication efficacy and accessibility for healthcare providers. In 2024, Kent Pharmaceuticals Limited reported a revenue of USD 123.
90 mn and an EBITDA of USD 15. 02 mn. The company’s revenue is primarily generated through B2B sales of its pharmaceutical products to hospitals and pharmacies, ensuring a streamlined supply chain through direct relationships with clients. The company plans to leverage its recent acquisition to expand its product offerings and enhance its market reach.
Specific plans for product launches and geographic expansion have not been detailed, but the focus remains on increasing their presence in the UK and broader European markets. The funding from the acquisition will be utilized to support these initiatives, with the most recent deal completed in September 2019.
Current Investors
Duke Street
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.kentpharm.co.uk
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Kent Pharmaceuticals Limited - timeline of key events
Kent Pharmaceuticals Limited - financials
| Fiscal Year Ended | Aug 31, 2010 | Aug 31, 2011 | Aug 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 61,665,105 | 71,831,996 | 73,304,022 | 159,000 | 273,000 | 273,000 | 273,000 | 273,000 | 273,000 | 273,000 | - | - | - | - | - |
| % Revenue Growth (YoY) | - | 16.5% | 2.0% | - | - | - | - | - | - | - | (100.0%) | - | - | - | - |
| EBITDA (USD) | 7,072,186 | 2,787,192 | 2,940,805 | 382,000 | 273,000 | 271,000 | 685,000 | 270,000 | (6,061,000) | 266,000 | - | - | - | - | - |
| Operating Income (USD) | 5,836,068 | 1,887,213 | 2,030,795 | 339,000 | 201,000 | 199,000 | 613,000 | 198,000 | (6,133,000) | 194,000 | (269,000) | (26,000) | - | - | - |
| Operating Margin | 9.5% | 2.6% | 2.8% | 213.2% | 73.6% | 72.9% | 224.5% | 72.5% | (2246.5%) | 71.1% | - | - | - | - | - |
| % EBITDA Margin | 11.5% | 3.9% | 4.0% | 240.3% | 100.0% | 99.3% | 250.9% | 98.9% | (2220.1%) | 97.4% | - | - | - | - | - |
| NET Income (USD) | 2,458,971 | 1,120,086 | 1,013,257 | 482,000 | (7,000) | (155,000) | 214,000 | (81,000) | (6,430,000) | (139,000) | 22,035,000 | (26,000) | - | - | - |
| % Net Margin | 4.0% | 1.6% | 1.4% | 303.1% | (2.6%) | (56.8%) | 78.4% | (29.7%) | (2355.3%) | (50.9%) | - | - | - | - | - |
Kent Pharmaceuticals Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Dalkeith Group | - | ||||||||
| Buyout | Completed | Kent Pharmaceuticals Limited | - |
Displaying 1 - 2 of 2
Kent Pharmaceuticals Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.